Healthcare company Daiichi Sankyo (TSE: 4568) announced on Monday that a Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd), jointly developed with biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN), has been granted Priority Review by the U.S. Food and Drug Administration (FDA).
The application is for the treatment of patients with advanced or metastatic epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NSCLC) who have previously undergone systemic therapies, including an EGFR-directed treatment.
Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate (ADC). The FDA's Priority Review designation is based on data from the TROPION-Lung05 phase 2 trial, supported by additional data from TROPION-Lung01 and TROPION-Pantumour01 trials. The FDA has also previously granted Breakthrough Therapy Designation (BTD) to Dato-DXd for this patient population. The FDA's action date, under the Prescription Drug User Fee Act (PDUFA), is set for 12 July 2025.
In clinical trials, datopotamab deruxtecan demonstrated significant tumour response in patients with previously treated advanced EGFR-mutated NSCLC. Safety data from these trials were consistent with prior reports, with no new safety concerns identified. The ongoing global development program includes multiple phase 3 trials, such as TROPION-Lung14 and TROPION-Lung15, evaluating Dato-DXd in combination with AstraZeneca's EGFR inhibitor, osimertinib.
The TROPION-Lung05 trial enrolled 137 patients globally, including those with actionable genomic alterations who had previously received multiple lines of treatment. Primary results from this trial were published in the Journal of Clinical Oncology in January 2025. Further clinical data from the TROPION-Lung01 and TROPION-Pantumour01 trials have also been presented at major oncology conferences.
Datopotamab deruxtecan is already approved in Japan for the treatment of HER2-negative breast cancer under the brand name DATROWAY and is under investigation in other markets. The global collaboration between Daiichi Sankyo and AstraZeneca, initiated in 2020, aims to advance the development of ADC therapies for various cancers.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review